Dantrolene and Daridorexant interaction
Dantrolene and Daridorexant: both prescribing labels describe an interaction that usually calls for monitoring, a dose change, or spacing the doses.
Usually manageable with monitoring or a dose change. Tell your pharmacist you take both.
What the FDA labels say
From the Dantrolene (RYANODEX dantrolene sodium) label · effective 2024-10-30
The concomitant use of sedative agents with RYANODEX may increase the risk of somnolence and dizziness.
Sedatives : Concomitant use with sedative agents may potentiate their effects ( 7.3 )
From the Daridorexant (QUVIVIQ) label · effective 2026-02-26
CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment.
Risk increases when used with other central nervous system (CNS) depressants.
Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment.
Dosage adjustments of QUVIVIQ and of concomitant CNS depressants may be necessary when administered together because of potentially additive effects.
Alcohol and Other CNS Depressants Clinical Implications: Concomitant use of alcohol or other CNS depressants with QUVIVIQ may lead to additive impairment of psychomotor performance and risk of CNS depression [see Clinical Pharmacology (12.2) ] .
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.